Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptomsZORYVE® (roflumilast) foam 0.3% is a ...

While "seborrheic dermatitis" (seb derm) may not be a household name, one of its most common visible symptoms—flakes that may ...

Add Yahoo as a preferred source to see more of our stories on Google. It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes ...

WESTLAKE VILLAGE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT) (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful ...

TORONTO, Oct. 21, 2024 /CNW/ - Arcutis Canada Inc., a commercial-stage company focused on delivering meaningful innovations in immuno-dermatology, is pleased to announce that Health Canada has ...

Arcutis Biotherapeutics, Inc. ARQT announced that the FDA has approved the new drug application (NDA) for Zoryve (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis in patients ...

If the skin under your facial hair is often red, irritated, itchy or flaky, the culprit could be a condition called seborrheic dermatitis. This is the same condition that causes dandruff on the scalp, ...

Please provide your email address to receive an email when new articles are posted on . Malassezia yeast may not be the root cause of seborrheic dermatitis. A new study showed that Zoryve was a ...

Please provide your email address to receive an email when new articles are posted on . A meta-analysis found a global pooled prevalence of 4.38% for seborrheic dermatitis. Overall prevalence in ...